Anti-obesity therapy for cardiovascular disease prevention: potential expected roles of glucagon-like peptide-1 receptor agonists

Obesity is characterized by visceral fat accumulation and various metabolic disturbances that cause metabolic syndrome and obesity-related cardiovascular diseases (ORCVDs). Hence, treatments targeting obesity should also prevent ORCVDs. Nonetheless, lifestyle modification therapy alone is still insu...

Descripción completa

Detalles Bibliográficos
Autores principales: Sawami, Kosuke, Tanaka, Atsushi, Node, Koichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Comment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9450447/
https://www.ncbi.nlm.nih.gov/pubmed/36068534
http://dx.doi.org/10.1186/s12933-022-01611-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9450447/
https://www.ncbi.nlm.nih.gov/pubmed/36068534
http://dx.doi.org/10.1186/s12933-022-01611-8

Ejemplares similares